Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Haemorrhage/shock
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseHaemorrhage/shockControlledC57BL/6Malen = n = 4 per group across three groups (sham, haemorrhagic sho…Intravenous1.7 mg/kg in vivo; 2, 5 and 10 micromol/L in isolated prima…Given at resuscitation, that is 60 min after onset of haemorrhagic shock
Model: Controlled haemorrhagic shock to mean arterial pressure of 30 plus or minus 2 mm Hg maintained for 60 min, followed by resuscitation with Lactated Ringer's solution at three times the shed blood volume
Haemorrhagic shock with resuscitation raised serum ALT, AST and LDH by roughly two to eight fold and produced hepatocyte ballooning degeneration and loss of sinusoidal architecture. Hinokitiol at 1.7 mg/kg markedly reduced these enzyme levels at 6 and 24 h after resuscitation, reversed caspase-3 ac…
Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.